BIND Therapeutics Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock

CAMBRIDGE, Mass.--()--BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins™, today announced that it is commencing an underwritten public offering of units consisting of shares of BIND’s common stock and warrants to purchase shares of BIND’s common stock. All of the units in the offering are to be sold by BIND.

Cowen and Company and Stifel are acting as joint book-running managers for the offering. JMP Securities is acting as lead manager and Oppenheimer & Co. is acting as co-manager for the offering.

The offering is being made pursuant to an effective shelf registration statement on Form S-3 that was filed with the U.S. Securities and Exchange Commission (SEC) on October 1, 2014. A preliminary prospectus supplement describing the terms of the offering will be filed with the SEC and form a part of the effective registration statement. Copies of the preliminary prospectus supplement and accompanying prospectus relating to this offering may be obtained, when available, by contacting Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, or by phone (631) 274-2806 or fax (631) 254-7140; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, by telephone at (415) 364-2720 or by email to syndprospectus@stifel.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor shall there be any sale of these securities, in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

Contacts

For BIND Therapeutics, Inc.
Media:
The Yates Network
Gina Nugent, 617-460-3579
gina@theyatesnetwork.com
or
Investors:
Stern Investor Relations, Inc.
Beth DelGiacco, 212-362-1200
BIND@sternir.com

Website

Release Summary

BIND is commencing an underwritten public offering of units consisting of shares of BIND’s common stock and warrants to purchase shares of BIND’s common stock.

BIND Therapeutics, Inc.